A 2026 federal temporary-scheduling action places mitragynine pseudoindoxyl, MGM-15, and MGM-16 under heightened Controlled Substances Act scrutiny. This analysis explains the order’s legal scope, why it distinguishes specified manufactured compounds from traditional botanical kratom, and what it means for research, laboratory analysis, and consumer-product transparency.
A federal guilty plea announced September 14, 2026 provides a documented look inside a grey-market anabolic steroid supply chain. DOJ described multi-kilogram steroid powders from China, subsequent production of injectable and oral products, private-label distribution, packaging materials, ledgers, cash, and firearms. The case illustrates why professional-looking bodybuilding products may still lack verifiable identity, potency, sterility, traceability, and regulated manufacturing controls.
A peer-reviewed August 2026 grey market semaglutide study tested whether adults could correctly handle and use peptide semaglutide obtained without a prescription. Participants completed only 44% of required steps, with errors capable of causing incorrect dosing, needle sticks and infections. The findings add a human-factors warning to FDA concerns about unapproved GLP-1 products, fraudulent labels and dosing errors.
A peer-reviewed study published July 30, 2026 found that tested compounded and follow-on semaglutide and liraglutide products contained impurity profiles different from their originator products. The findings add a scientific layer to discussion of compounded GLP-1 quality: the issue is not only whether a vial contains the labeled peptide, but whether manufacturing and storage create altered peptide forms that may affect stability or immune recognition.
A series of FDA notifications from August and September 2026 found undeclared prescription drugs, toxic plant compounds, and industrial chemicals in products marketed for weight loss. The findings reveal how the grey-market slimming market extends beyond counterfeit GLP-1s and why “natural” labels provide no reliable assurance of composition.
A cluster of seven acute liver-injury cases in Victoria has become one of the clearest recent warnings about the danger of counterfeit retatrutide. The products were sold outside regulated medical channels and may not have contained clinical-trial retatrutide at all. New testing also found major discrepancies between the labeled and measured contents of black-market vials, reinforcing the difference between a promising investigational compound and an unverified product sold under its name.
A federal indictment announced August 17, 2026 alleges that an Illinois man impersonated physicians, misused National Provider Identifier information, and helped customers obtain GLP-1 and other prescription medications without legitimate authorization. The case shows how grey-market risk can extend beyond counterfeit products into prescription fraud, identity theft, and pharmacy-benefit abuse.
A randomized, placebo-controlled 2026 study tested N-PEP-12 in 276 adults aged 50 to 75 with subjective cognitive complaints. The trial reported exploratory signals in attention, working memory, mood, and stress measures, but its primary statistical interpretation and proprietary composition require careful reading.
A new FDA safety alert tied at least 30 adverse-event reports to compounded intravenous glutathione made with dietary-supplement-grade material. The warning exposes a broader quality problem: an ingredient suitable for oral supplement manufacturing is not automatically suitable for sterile injection. Here is what the August 2026 alert, related recalls, and endotoxin science mean for compounding oversight and consumer awareness.
A peer-reviewed August 2026 study reports fewer new cases of cognitive impairment among older adults with HFpEF, obesity, and type 2 diabetes who received oral semaglutide rather than matched DPP-4 inhibitor users. The 77% lower adjusted risk is notable, but this observational study cannot establish dementia prevention or a direct brain-protective effect.
